Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag

Zacks2023-10-02

Baudax Bio BXRX announced that the FDA has granted the Orphan Drug designation to its next-generation, FVIII specific Treg therapy, TI-168, for treating patients with hemophilia A with inhibitors. The...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2372683898?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","is_english":true,"pubTime":"2023-10-02 21:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2372683898","market":"us","top_or_hot":-1,"title":"Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag","media":"Zacks","content":"<div>\n<p>Baudax Bio BXRX announced that the FDA has granted the Orphan Drug designation to its next-generation, FVIII specific Treg therapy, TI-168, for treating patients with hemophilia A with inhibitors.\nThe...</p>\n\n<a href=\"https://finance.yahoo.com/news/baudaxs-bxrx-hemophilia-drug-gets-131500420.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-02 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/baudaxs-bxrx-hemophilia-drug-gets-131500420.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Baudax Bio BXRX announced that the FDA has granted the Orphan Drug designation to its next-generation, FVIII specific Treg therapy, TI-168, for treating patients with hemophilia A with inhibitors.\nThe...</p>\n\n<a href=\"https://finance.yahoo.com/news/baudaxs-bxrx-hemophilia-drug-gets-131500420.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/baudaxs-bxrx-hemophilia-drug-gets-131500420.html","article_id":"2372683898","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2372683898","pubTimestamp":1696252500,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Baudax Bio BXRX announced that the FDA has granted the Orphan Drug designation to its next-generation, FVIII specific Treg therapy, TI-168, for treating patients with hemophilia A with inhibitors.The designation is granted to experimental treatments intended for rare diseases affecting less than 200,000 individuals in the United States. It expedites the development and review of drugs, and also grants seven years of post-approval marketing exclusivity.In June 2022, the FDA approved an investigational new drug application , seeking to initiate a clinical study on TI-168 to treat hemophilia A patients with inhibitors. Following the approval, BXRX plans to initiate phase I/IIa study on TI-168 by early 2024.Hemophilia A is a rare genetic blood disorder which is caused by a missing clotting protein known as FVIII. The protein prevents normal blood from clotting. If the blood doesn’t clot properly, it can lead to painful bleeding inside the joints that can cause scarring and damage.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SNY":"赛诺菲安万特","BK4592":"伊斯兰概念","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BXRX":"Baudax Bio, Inc.","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","PFE":"辉瑞","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4550":"红杉资本持仓","RHHBY":"罗氏控股","BK4588":"碎股","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4568":"美国抗疫概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","03165":"华夏欧优股对冲","LU0058720904.USD":"联博国际健康护理基金A"},"translate_title":"Baudax血友病A药物获得FDA孤儿药标签","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1,"RHHBY":1,"BXRX":1,"PFE":0.9,"03165":0.6},"content_text":"Baudax Bio BXRX announced that the FDA has granted the Orphan Drug designation to its next-generation, FVIII specific Treg therapy, TI-168, for treating patients with hemophilia A with inhibitors.\nThe designation is granted to experimental treatments intended for rare diseases affecting less than 200,000 individuals in the United States. It expedites the development and review of drugs, and also grants seven years of post-approval marketing exclusivity.\nIn June 2022, the FDA approved an investigational new drug application (IND), seeking to initiate a clinical study on TI-168 to treat hemophilia A patients with inhibitors. Following the approval, BXRX plans to initiate phase I/IIa study on TI-168 by early 2024.\nHemophilia A is a rare genetic blood disorder which is caused by a missing clotting protein known as FVIII. The protein prevents normal blood from clotting. If the blood doesn’t clot properly, it can lead to painful bleeding inside the joints that can cause scarring and damage.\nSeveral other companies like Genentech (subsidiary of Roche [RHHBY]), Sanofi SNY and Pfizer PFE have developed or are developing treatment for hemophilia A.\nRoche’s Hemlibra (emicizumab) was the first approved treatment for the disease. Emicizumab is a bispecific antibody mimicking the action of FVIII. It is administered subcutaneously. Hemlibra continues to perform well and the drug is one of the top contributors to Roche’s sales growth. In the first half of 2023, RHHBY generated revenues of CHF 2.1 billion from the drug, indicating 20% growth year over year.\nSanofi’sAltuviiio (efanesoctocog alfa), a new class of FVIII therapy for hemophilia A, was approved by the FDA in February 2023. The drug was launched in the United States in March 2023. Sanofi generated sales of 19 million euros from Altuviiio in the first half of 2023.\nPfizer is developing its investigational anti-tissue factor pathway inhibitor, marstacimab, as a treatment for hemophilia A or B patients, without inhibitors to FVIII or Factor IX. In May, the company reported upbeat data from the phase III BASIS study that evaluated marstacimab for hemophilia A or B patients. The study met its primary endpoints, which showed that those treated with marstacimab achieved a statistically significant and clinically relevant reduction in annualized bleeding rate compared with the current standard-of-care treatment for hemophilia patients.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nSanofi (SNY) : Free Stock Analysis Report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nBaudax Bio, Inc. (BXRX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2372683898"}